Effects of pegylated interferon‐α‐2a monotherapy on growth in Japanese children with chronic hepatitis C. Issue 3 (24th April 2013)
- Record Type:
- Journal Article
- Title:
- Effects of pegylated interferon‐α‐2a monotherapy on growth in Japanese children with chronic hepatitis C. Issue 3 (24th April 2013)
- Main Title:
- Effects of pegylated interferon‐α‐2a monotherapy on growth in Japanese children with chronic hepatitis C
- Authors:
- Tsunoda, Tomoyuki
Inui, Ayano
Kawamoto, Manari
Sogo, Tsuyoshi
Komatsu, Haruki
Fujisawa, Tomoo - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hepr12118-sec-0001" sec-type="section"> <title>Aim</title> <p>The relationship between pegylated interferon (PEG IFN)‐α‐2a and growth of children with chronic hepatitis C (CHC) remains unclear. This study was to evaluate the effects of PEG IFN‐α‐2a on growth.</p> </sec> <sec id="hepr12118-sec-0002" sec-type="section"> <title>Methods</title> <p>From 2003–2012, we prospectively analyzed the data of children with CHC through mother‐to‐infant transmission. They were all treatment naive and were treated with PEG IFN‐α‐2a monotherapy.</p> </sec> <sec id="hepr12118-sec-0003" sec-type="section"> <title>Results</title> <p>Among 31 children (19 boys, 12 girls; median age, 6 years) treated with monotherapy during the study period, 21 children (13 boys, eight girls; median age, 7 years) were statistically analyzed. The median treatment period of the 21 children was 48 weeks (range, 48–72). Z‐scores of height and weight before treatment, at the end of treatment and 1 year after treatment were −0.05, −0.24 and −0.12 (height), and +0.11, −0.23 and −0.05 (weight). Both Z‐scores were significantly decreased at the end of the treatment. One year after treatment, Z‐scores of height and bodyweight were significantly improved compared with that of end of treatment but were still lower than those before treatment, with statistical significance. Z‐scores of height growth velocity was significantly<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="hepr12118-sec-0001" sec-type="section"> <title>Aim</title> <p>The relationship between pegylated interferon (PEG IFN)‐α‐2a and growth of children with chronic hepatitis C (CHC) remains unclear. This study was to evaluate the effects of PEG IFN‐α‐2a on growth.</p> </sec> <sec id="hepr12118-sec-0002" sec-type="section"> <title>Methods</title> <p>From 2003–2012, we prospectively analyzed the data of children with CHC through mother‐to‐infant transmission. They were all treatment naive and were treated with PEG IFN‐α‐2a monotherapy.</p> </sec> <sec id="hepr12118-sec-0003" sec-type="section"> <title>Results</title> <p>Among 31 children (19 boys, 12 girls; median age, 6 years) treated with monotherapy during the study period, 21 children (13 boys, eight girls; median age, 7 years) were statistically analyzed. The median treatment period of the 21 children was 48 weeks (range, 48–72). Z‐scores of height and weight before treatment, at the end of treatment and 1 year after treatment were −0.05, −0.24 and −0.12 (height), and +0.11, −0.23 and −0.05 (weight). Both Z‐scores were significantly decreased at the end of the treatment. One year after treatment, Z‐scores of height and bodyweight were significantly improved compared with that of end of treatment but were still lower than those before treatment, with statistical significance. Z‐scores of height growth velocity was significantly increased after the treatment (+0.71), compared with that during treatment (−2.25).</p> </sec> <sec id="hepr12118-sec-0004" sec-type="section"> <title>Conclusion</title> <p>PEG IFN‐α‐2a has an inhibitory effect on children's growth, and Z‐scores of height and bodyweight were decreased at the end of treatment. Although Z‐scores improved after the treatment, they had not returned to the baseline level 1 year after the treatment.</p> </sec> </abstract> … (more)
- Is Part Of:
- Hepatology research. Volume 44:Issue 3(2014:Mar.)
- Journal:
- Hepatology research
- Issue:
- Volume 44:Issue 3(2014:Mar.)
- Issue Display:
- Volume 44, Issue 3 (2014)
- Year:
- 2014
- Volume:
- 44
- Issue:
- 3
- Issue Sort Value:
- 2014-0044-0003-0000
- Page Start:
- 251
- Page End:
- 258
- Publication Date:
- 2013-04-24
- Subjects:
- Liver -- Diseases -- Periodicals
Liver Diseases -- Periodicals
Foie -- Maladies -- Périodiques
616.362 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09284346 ↗
http://firstsearch.oclc.org/journal=1386-6346;screen=info;ECOIP ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1872-034X ↗
http://www.sciencedirect.com/science/journal/13866346 ↗
http://www3.interscience.wiley.com/journal/118507311/home ↗
http://www.blackwell-synergy.com/rd.asp?goto=journal&code=hep ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/hepr.12118 ↗
- Languages:
- English
- ISSNs:
- 1386-6346
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4295.845000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4300.xml